About Us

CSPC is a national innovative enterprise integrating R & D, production and sales of innovative drugs. The Group has total assets of 49 billion yuan and 27,000 employees. The Hong Kong-listed company (01093.HK) ranks among the 100 billion market capitalization clubs and is a constituent stock of the Hang Seng Index. It is also the first pharmaceutical stock in the 50 years since the establishment of the Hang Seng Index. On March 22, 2019, the subsidiary company New Novartis (300765.SZ) was successfully listed on the GEM, and CSPC achieved a new era of "red chip + A" financing pattern. Since its establishment, with the strong support of all walks of life, CSPC has been constantly innovating and making progress, achieving sustained, healthy and rapid development. At present, there are more than 10 pharmaceutical production bases, and the products are sold in more than 100 countries and regions around the world. There are 34 varieties of single varieties with sales of over 100 million yuan. In 2019, the Group achieved sales revenue of 36.456 billion yuan and paid 3.04 billion yuan in various taxes, making outstanding contributions to promoting the development of China's pharmaceutical industry and regional economic construction. Adhering to the corporate mission of "doing medicine well for China and serving the world", CSPC continues to develop innovative products and continuously enhance its production capacity. At present, the Group has more than 1,000 production symbols and has a broad product portfolio that can meet Health needs of people with different diseases. At present, CSPC has established an integrated R & D system at home and abroad, with R & D and clinical centers in Beijing, Shanghai and Shijiazhuang, and clinical offices in 8 cities including Wuhan and Shenyang; in California and Texas There are R & D centers and clinical centers in Sri Lanka and New Jersey, with annual R & D expenditures exceeding 2 billion yuan. The whole group has 1800 R & D personnel, including more than 200 doctoral talents and high-end returnees. At present, the Group has about 300 innovative drug product projects, including more than 50 large molecular innovative drugs, more than 40 small molecular innovative drugs, and more than 20 new formulations. CSPC has established a complete four-level quality management system, and all pharmaceutical production lines have passed the new GMP certification. At present, CSPC has obtained 12 CEP certificates and 35 DMF registration numbers, and 25 products have successfully passed the on-site inspection by the US FDA. CSPC API Marketing Company established in Dec., 9th, 2015, and takes charge of the domestic and international sales of CSPC API. CSPC API Marketing Company takes charge of the product sales of CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., CSPC Innovation Pharmaceutical Co., Ltd., Hebei Huarong Pharmaceutical Co., Ltd., CSPC Shengxue Dextrose Co., Ltd., CSPC Zhongnuo (Shijiazhuang) Pharmaceutical Co., Ltd., Inner Mongolia Changsheng Pharmaceutical Co., Ltd., Hebei Union Pharmaceutical Co., Ltd., Inner Mongolia Zhongrun Pharmaceutical Co., Ltd., CSPC has the largest APIs production capability; many of APIs/Intermediates have the No.1 sales quantity in the worldwide. Looking to the future, CSPC will continue to strengthen innovation and make CSPC a globally-respected and innovative pharmaceutical company with wide influence. Dedicate to the society with more, newer and better medicines, and make great strides on the road of continuously leading innovation and building excellent stone medicine!